Novanta (NOVT) Q2 2025: New Product Revenue Surges 50%, Securing Growth in Robotics and Surgery
Novanta’s Q2 highlighted a decisive pivot to high-growth robotics and advanced surgery, with new product revenue up over 50% and design wins more than doubling year over year. Despite macro and trade headwinds, robust bookings and contract momentum signal sequential growth into 2026. The company’s focus on physical AI, medical consumables, and tariff mitigation is recalibrating its earnings power and market positioning for the next cycle.
Summary
- Secular Growth Bets Accelerate: Physical AI and advanced surgery are now core revenue engines, with strong customer adoption and contract wins.
- Operational Leverage in Focus: Cost actions and regional manufacturing are offsetting tariff headwinds and supporting resilient margins.
- Acquisition Pipeline Set to Expand: Balance sheet flexibility and integration success position Novanta for further portfolio transformation.
Performance Analysis
Novanta delivered Q2 results that met or exceeded guidance for sales, margins, and profit, despite a fluid macro environment and persistent trade friction. Reported revenue growth of 2% and organic revenue decline of 2% masked the underlying strength in new product sales, which surged over 50% year over year and now represent a vitality index of 21% of total sales. Bookings rose 10% YoY and 20% sequentially, reflecting a strengthening demand outlook and improved customer visibility, particularly in advanced surgery and robotics.
Segment dynamics were mixed: Medical markets (54% of sales) held flat, but advanced surgery posted double-digit growth, fueled by new launches in surgical robotics and minimally invasive surgery. Automation enabling technology (46% of sales) grew 4% YoY, led by a 16% jump in robotics and automation. In contrast, precision medicine and industrial capital equipment saw YoY declines, though both stabilized sequentially and are expected to improve into year-end. Gross margins held at 46%, flat sequentially, as tariff costs were contained through mitigation strategies. Operating cash flow was pressured by inventory and tax timing, but is expected to rebound in Q3.
- New Product Ramp: Over 50% YoY growth in new product sales, with >150% increase in design wins, especially in medical and robotics.
- Advanced Surgery Outperformance: Double-digit growth sustained, driven by next-gen smoke evacuating insufflators and strong procedural volumes.
- Tariff and Trade Navigation: $4 million YTD tariff impact managed through cost actions, with regional manufacturing and cost reduction underway.
Underlying demand signals and execution on innovation are positioning Novanta for sequential growth through 2025 and a stronger 2026, even as legacy segments stabilize from recent troughs.
Executive Commentary
"Our long-term growth strategy remains focused on winning in markets with long-term secular tailwinds, such as precision and AI-driven robotics and automation, advancement of the invasive and robotic surgery, and precision medicine."
Matthias Glastra, Chair and Chief Executive Officer
"We saw a continued strong pace of bookings in both our segments, demonstrating not only stabilization of demand, but also increased demand outlook for 2026 and the continued strong momentum of new product launches."
Robert Buckley, Chief Financial Officer
Strategic Positioning
1. Physical AI and Robotics as Growth Pillars
Novanta is doubling down on physical AI—robotics that combine touch, sensing, and motion control— with design wins and contracts in warehouse automation and humanoid robotics. The $50 million warehouse automation contract, set to ramp in 2026, exemplifies the company’s shift toward serving the next wave of automation, leveraging proprietary servo drives and haptic sensing. Management estimates a $1 billion addressable market by 2030 in these applications, with platform technologies spanning warehouse, humanoid, and surgical robotics.
2. Advanced Surgery and Medical Consumables Expansion
The advanced surgery business remains a standout, with product launches in smoke evacuation and minimally invasive devices driving double-digit growth and strong adoption. Medical consumables now account for 15% of sales, and are growing at a double-digit pace, supported by deep OEM partnerships and exclusive design-ins. Two major design wins in insufflators and endoscopy pumps further cement multi-year visibility and stickiness in this segment.
3. Tariff Response and Regional Manufacturing
Tariff headwinds, especially in U.S.-China trade, prompted Novanta to accelerate regional manufacturing and cost reduction, with restructuring charges of $20 to $25 million expected. The “in China, for China” strategy is yielding 15% YoY China sales growth, even as U.S. exports to China remain muted. Design win activity with Chinese customers is robust, signaling confidence in Novanta’s mitigation plans and technology roadmap.
4. Portfolio Transformation and Acquisition Pipeline
The acquisition of Keyon Technologies, RFID and AI-enabled inventory software, is already exceeding expectations, expanding recurring revenue and software content in medical markets. With a newly upsized $1 billion credit facility and $350 million accordion, Novanta is positioned to “lean in hard” for further portfolio evolution, targeting high-growth, high-margin, and recurring revenue businesses.
5. Innovation-Driven Operating Model
Novanta’s operating model is anchored by the Novanta Growth System (NGS), a proprietary process optimization and innovation framework. This has enabled capacity expansion without major capex, shortened lead times, and improved margin resilience, particularly as volumes ramp in new robotics and medical programs. The company’s R&D intensity remains high at 10% of sales, supporting a steady cadence of new launches.
Key Considerations
Novanta’s Q2 underscores a business model in transition, with innovation and secular market exposure offsetting legacy cyclicality and trade disruption. Investors should weigh the following:
Key Considerations:
- Physical AI Adoption Curve: Rapid contract wins in warehouse and humanoid robotics validate Novanta’s platform, but execution on multi-year ramps and competitive differentiation will be critical.
- Medical Consumables Stickiness: Expansion into consumables and embedded software is structurally raising margins and recurring revenue, but regulatory and OEM dependency remain watchpoints.
- Tariff and Trade Volatility: While mitigation is on track, $35 million in China-related revenue remains at risk pending manufacturing transfers and trade clarity.
- Cash Flow and Inventory Management: Q2 cash flow was pressured by inventory and tax timing, but normalization is expected as the trade environment stabilizes.
- Acquisition Execution: Keyon integration is ahead of plan, and a robust M&A pipeline could accelerate portfolio transformation if valuation discipline holds.
Risks
Trade policy uncertainty and tariff escalation remain the most immediate risk, with $35 million of China-exposed revenue contingent on successful regionalization and customer order behavior. Legacy segments like precision medicine and industrial equipment are stabilizing but still exposed to macro and funding cycles, while new product ramps carry execution risks as volumes scale. Regulatory shifts in medical device markets and integration of future acquisitions also present potential headwinds.
Forward Outlook
For Q3 2025, Novanta guided to:
- Revenue of $244 million to $247 million, flat to up 1% YoY and 1% to 2% sequentially.
- Adjusted gross margin near 46%, with temporary cost redundancy from regional manufacturing persisting into Q3.
For full-year 2025, management reissued guidance:
- Revenue of $970 million to $985 million, 2% to 4% growth (organic revenue flat to down 1%, with Keyon as the delta).
- Adjusted EBITDA of $225 million to $230 million (23% margin), 7% to 10% YoY growth.
- Adjusted EPS of $3.22 to $3.36, 5% to 9% YoY growth.
Management cited:
- Continued strength in advanced surgery and robotics, offset by muted China exports and legacy segment stabilization.
- Tariff mitigation, cost actions, and acquisition acceleration as key levers for 2025 and beyond.
Takeaways
Novanta’s Q2 signals a business shifting from legacy cyclicality to innovation-driven secular growth, with new product ramps, design wins, and physical AI contracts driving future earnings power.
- Innovation-Led Growth: Robust new product and design win momentum in advanced surgery and robotics is underpinning sequential growth and multi-year visibility.
- Margin Resilience: Operational discipline, cost actions, and regional manufacturing are containing tariff headwinds and supporting stable gross margins.
- Portfolio Evolution: Acquisition success and pipeline depth set the stage for further transformation into higher-margin, recurring revenue businesses.
Conclusion
Novanta’s Q2 2025 demonstrates a clear pivot to high-growth, innovation-led markets, with secular tailwinds in robotics and advanced surgery offsetting legacy softness and trade volatility. Execution on new product ramps, tariff mitigation, and disciplined M&A will be central to sustaining this trajectory into 2026 and beyond.
Industry Read-Through
Novanta’s results reinforce the accelerating adoption of physical AI across industrial and medical markets, with warehouse automation and surgical robotics emerging as key battlegrounds for OEM differentiation. The “in China, for China” manufacturing strategy is increasingly critical for global suppliers navigating trade friction, and is likely to be emulated across the automation and medtech sectors. RFID, machine vision, and embedded software are gaining traction as OEMs seek recurring revenue and regulatory compliance, suggesting that suppliers with platform technologies and integration capabilities will be best positioned as secular winners in the next cycle.